Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD: Case 1
Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD
Case Scenario 1:
January 2015
- The patient is a 61-year-old male who was diagnosed with ISS stage II MM.
- Performance status 0.
- He was treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction.
- He achieved a partial response with RVD.
- He then had an autologous stem cell transplantation and achieved MRD negativity.
- He was started on lenalidomide maintenance of 15 mg.
April 2016
- Patient was experiencing back pain, loss of appetite and weight loss.
- Upon relapse cytogenetics showed a 17p deletion detected by FISH, demonstrating progression of his disease.
- Beta-2 microglobulin=4.0 mg/dL, Hg=9 g/dL, creatinine=1.2 mg/dL, multiple bone lesions, bone marrow biopsy=70% plasma cells.
- Performance status 1.
- Based on these criteria he was diagnosed with standard-risk multiple myeloma.
- He was started on daratumumab, bortezomib, and dexamethasone.
Related Videos
Related Content
Isa-Kd Stands Out Among Subsequent Regimens in Multiple Myeloma
April 4th 2024Article
During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.
Read More
Benefit of Dara-Rd Maintained Across Age Groups in Transplant-Ineligible NDMM
April 2nd 2024Article
During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the SWOG S0777 and MAIA trials in transplant-ineligible newly diagnosed multiple myeloma in the second article of a 2-part series.
Read More
